It has been shown in previous studies that peptides designed to inhibit Fis1/Drp1 and Mff/Drp1 PPIs may provide therapeutic benefits in animal models of neurodegenerative diseases (Qi et al., 2013; Joshi et al., 2019) and CVDs (Disatnik et al., 2013). Here, DNM1L is linked to neurodegenerative disease.